Page last updated: 2024-12-06
3-hydroxycarbofuran
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
3-hydroxycarbofuran: main metabolite of carbofuran [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 27975 |
| CHEMBL ID | 1867082 |
| CHEBI ID | 174216 |
| SCHEMBL ID | 3400466 |
| MeSH ID | M0091464 |
Synonyms (48)
| Synonym |
|---|
| 3-hydroxy-carbofuran |
| (3-hydroxy-2,2-dimethyl-3h-1-benzouran-7-yl) n-methylcarbamate |
| CHEBI:174216 |
| carbamic acid, methyl-, 2,3-dihydro-2,2-dimethyl-3-hydroxy-7-benzofuranyl ester |
| ccris 9207 |
| brn 1383873 |
| 3-hydroxycarbofuran |
| 3,7-benzofurandiol, 2,3-dihydro-2,2-dimethyl-, 7-(methylcarbamate) |
| NCGC00163948-01 |
| 36550_riedel |
| 16655-82-6 |
| carbofuran-3-hydroxy |
| 3,7-benzofurandiol, 2,3-dihydro-2,2-dimethyl- 7-(methylcarbamate) |
| 3,7-benzofurandiol, 2,3-dihydro-2,2-dimethyl-, 7-(methylcarbamate) (9ci) |
| 37896_riedel |
| FT-0669337 |
| SCHEMBL3400466 |
| (3-hydroxy-2,2-dimethyl-3h-1-benzofuran-7-yl) n-methylcarbamate |
| unii-7j7n7a61bj |
| 7j7n7a61bj , |
| 5-17-05-00204 (beilstein handbook reference) |
| 3-hydroxy carbofuran |
| AKOS022181449 |
| RHSUJRQZTQNSLL-UHFFFAOYSA-N |
| 3-hydroxy-2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl methylcarbamate # |
| carbamic acid, methyl-, 2,3-dihydro-3-hydroxy-2,2-dimethyl-7-benzofuranyl ester |
| carbofuran, 3-hydroxy |
| carbofuran 3-oh |
| CHEMBL1867082 |
| DTXSID2037506 |
| 3-hydroxy-2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl n-methylcarbamate |
| carbofuran-3-hydroxy, pestanal(r), analytical standard |
| carbofuran-3-hydroxy 100 microg/ml in ethyl acetate |
| 2,3-dihydro-2,2-dimethyl-3,7-benzofurandiol 7-(methylcarbamate) |
| J-010297 |
| pesticide3_3-hydroxycarbofuran_c12h15no4_3,7-benzofurandiol, 2,3-dihydro-2,2-dimethyl-, 7-(methylcarbamate) |
| 3-hydroxycarbofuran; methylcarbamic acid |
| carbofuran-3-oh |
| 3-oh-carbofuran |
| 3-hydroxy-2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl methylcarbamate |
| 3-hydroxy-2,2-dimethyl-2,3-dihydrobenzofuran-7-yl methylcarbamate |
| 3-hydrocarbofuran |
| 3-(2-oxo-propyl)-benzoicacidethylester |
| 3,7-benzofurandiol, 2,3-dihydro-2,2-dimethyl-, 7-(n-methylcarbamate) |
| Q27268397 |
| 1ST20259 |
| 3-hydroxycarbofuran 100 microg/ml in acetonitrile |
| PD076405 |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therefore, a dosage of 420 g active ingredient per 100 kg seed was recommended, which could be considered as safe to human beings and animals." | ( Residues of carbosulfan and its metabolites carbofuran and 3-hydroxy carbofuran in rice field ecosystem in China. He, HM; Hu, XQ; Wang, Q; Yu, JZ; Zhang, CP; Zhu, YH, 2016) | 0.43 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| 1-benzofurans | A member of the class of benzofurans consisting of a 1-benzofuran skeleton and its substituted derivatives thereof. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (3)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 0.0010 | 0.3758 | 27.4851 | 61.6524 | AID588527 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 0.0158 | 0.0100 | 39.5371 | 1,122.0200 | AID588545 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 54.4827 | 0.0006 | 27.2152 | 1,122.0200 | AID651741 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Research
Studies (24)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (16.67) | 18.7374 |
| 1990's | 2 (8.33) | 18.2507 |
| 2000's | 5 (20.83) | 29.6817 |
| 2010's | 9 (37.50) | 24.3611 |
| 2020's | 4 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 27.38
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.38) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (3.70%) | 6.00% |
| Case Studies | 2 (7.41%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 24 (88.89%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||